{"id":"W2590905635","doi":"10.1200/jco.2016.34.4_suppl.tps477","title":"LAPACT: An open-label, multicenter phase II trial of <i>nab</i>-paclitaxel (<i>nab</i>-P) plus gemcitabine (Gem) in patients (pts) with locally advanced pancreatic cancer (LAPC).","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Gemcitabine; Internal medicine; Clinical endpoint; Discontinuation; Nab-paclitaxel; Performance status; Oncology; Cancer; Progressive disease; Gastroenterology; Surgery; Clinical trial; Urology; Chemotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001744781,0.002031368,0.001376039,0.0005447509,0.0004601166,0.001302275,0.001401126,0.001254259,0.00663255],"category_scores_gemma":[0.001323733,0.0005974282,0.001055936,0.0004900145,0.001390853,0.00129468,0.0007699985,0.003567663,0.001274547],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000994297,"about_ca_system_score_gemma":0.001970835,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001839445,"about_ca_topic_score_gemma":0.004008174,"domain_scores_codex":[0.9996061,0.0002298369,0.00001583369,0.00004197265,0.00003384409,0.00007239681],"domain_scores_gemma":[0.999089,0.0001085792,0.0002151349,0.00005343924,0.00003867245,0.0004951979],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8568959,0.04386511,0.005046978,0.0009353161,0.0005544501,0.0003329322,0.0002360891,0.003128202,0.02048013,0.0004148487,0.008179531,0.05993038],"study_design_scores_gemma":[0.7657483,0.2236014,0.004487014,0.00005476988,0.0002473061,0.0002587135,0.00006441006,0.001106749,0.001807741,0.0001637018,0.002432617,0.00002731542],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9772527,0.003652039,0.001089888,0.001165048,0.0003077172,0.00825172,0.003338255,0.0004295722,0.004513115],"genre_scores_gemma":[0.9720171,0.002870298,0.002716833,0.001805077,0.0003530133,0.009441025,0.006001741,0.00007262983,0.004722189],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00663255,"threshold_uncertainty_score":0.02218807,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05381307791062821,"score_gpt":0.4241843371871553,"score_spread":0.3703712592765271,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}